Combination Therapy in Alzheimer's Disease: a Review of Current Evidence

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2004 Nov 4

PMID 15521788

Citations 29

Authors

Beate Schmitt

Tanja Bernhardt

Hans-Juergen Moeller

Isabella Heuser

Lutz Frolich

Affiliations

Soon will be listed here.

Abstract

Treating dementia has become a major challenge in clinical practice. Presently, acetylcholinesterase inhibitors are the first-line drugs in the treatment of Alzheimer's disease (AD). These options are now complemented by memantine, which is approved for the treatment of moderate-to-severe AD. Altogether, a minimum of six agent classes already exist, all of which are approved for clinical use and are either already being tested or ready for phase III clinical trials for the treatment of AD. These include cholinesterase inhibitors, blockers of the NMDA receptor, antioxidants or blockers of oxidative deamination (including Gingko biloba), anti-inflammatory agents, neurotrophic factors (including hormone replacement therapy and drugs acting on insulin signal transduction) and antiamyloid agents (including cholesterol-lowering therapy). These approaches hold promise for disease modification and have a potential to be used as combination therapy for cognitive enhancement. Presently, only nine clinical studies have been published that have investigated the effects of a combination regimen on cognitive performance or AD. Among those, one study was conducted in elderly cognitively intact persons; the others involved patients with AD. Only five of the treatment studies followed a randomised, controlled design. Not all studies favoured the superior efficacy of combination therapy over monotherapy. Some studies, however, showed some evidence for synergistic combination effects of symptomatic therapy, including delay or prevention of disease progression in AD patients. In addition, six studies investigated the effects of AChE inhibitor in combination with antipsychotic or antidepressant therapy on behavioural aspects of AD symptomatology. In four of those studies there were indications that combination therapy had greater efficacy over monotherapy. The treatment of AD patients requires optimised options for all stages of illness based on the available drugs. There is a great need for further well designed studies on combination therapy in AD.

Citing Articles

Cellular Mechanisms of Cognitive Enhancement: The Modulation of the Firing Activity and the Responsiveness of Rat Hippocampal Neurons by Memantine and Alpha7 Nicotinic Acetylcholine Receptor Ligands.

Nagy L, Bali Z, Ledneczki I, Nemethy Z, Lendvai B, Hernadi I ASN Neuro. 2024; 16(1):2371160.

PMID: 39024573 PMC: 11262468. DOI: 10.1080/17590914.2024.2371160.

L. Seed and Attenuate Oxidative Stress Induced by Hydrogen Peroxide in SH-SY5Y Cells.

He M, Park C, Shin Y, Kim J, Cho E Foods. 2023; 12(19).

PMID: 37835271 PMC: 10572336. DOI: 10.3390/foods12193617.

Deciphering the Role of Peroxisome Proliferator-activated Receptor α and Phosphodiesterase Type 5 Targets in Alzheimer's Disease.

Sose P, Kale P, Doshi G CNS Neurol Disord Drug Targets. 2023; 23(8):956-970.

PMID: 37670711 DOI: 10.2174/1871527323666230904150841.

Combination of epigallocatechin 3 gallate and curcumin improves D-galactose and normal-aging associated memory impairment in mice.

Rahman M, Shuvo A, Apu M, Bhakta M, Islam F, Rahman M Sci Rep. 2023; 13(1):12681.

PMID: 37542120 PMC: 10403524. DOI: 10.1038/s41598-023-39919-4.

Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer's Disease.

Fihurka O, Wang Y, Hong Y, Lin X, Shen N, Yang H Biomolecules. 2023; 13(2).

PMID: 36830601 PMC: 9953380. DOI: 10.3390/biom13020232.

References

Cummings J . Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003; 11(2):131-45. View

Fuchsberger T, Padberg F, Faltraco F, Moller H, Hampel H . [Starting Alzheimer therapy in early stages whenever possible. Activities of daily living remain intact longer]. MMW Fortschr Med. 2002; 144(20):36-9. View

Fassbender K, Masters C, Beyreuther K . Alzheimer's disease: an inflammatory disease?. Neurobiol Aging. 2000; 21(3):433-6; discussion 451-3. DOI: 10.1016/s0197-4580(00)00147-0. View

Monk D, Brodaty H . Use of estrogens for the prevention and treatment of Alzheimer's disease. Dement Geriatr Cogn Disord. 2000; 11(1):1-10. DOI: 10.1159/000017206. View

Tabet N, Feldman H . Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev. 2002; (2):CD003673. PMC: 6669267. DOI: 10.1002/14651858.CD003673. View

Schneider L, Olin J, Pawluczyk S . A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry. 1993; 150(2):321-3. DOI: 10.1176/ajp.150.2.321. View

Jick H, Zornberg G, Jick S, Seshadri S, Drachman D . Statins and the risk of dementia. Lancet. 2000; 356(9242):1627-31. DOI: 10.1016/s0140-6736(00)03155-x. View

Hogervorst E, Yaffe K, Richards M, Huppert F . Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2002; (3):CD003799. DOI: 10.1002/14651858.CD003799. View

Paleologos M, Cumming R, Lazarus R . Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol. 1998; 148(1):45-50. DOI: 10.1093/oxfordjournals.aje.a009559. View

10.

Toran-Allerand C, Miranda R, Bentham W, Sohrabji F, Brown T, Hochberg R . Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A. 1992; 89(10):4668-72. PMC: 49144. DOI: 10.1073/pnas.89.10.4668. View

11.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E . A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57(4):613-20. DOI: 10.1212/wnl.57.4.613. View

12.

Hager K, Marahrens A, Kenklies M, Riederer P, Munch G . Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. Arch Gerontol Geriatr. 2001; 32(3):275-82. DOI: 10.1016/s0167-4943(01)00104-2. View

13.

Saver J, Kalafut M . Combination therapies and the theoretical limits of evidence-based medicine. Neuroepidemiology. 2001; 20(2):57-64. DOI: 10.1159/000054762. View

14.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

15.

Prehn J, Krieglstein J . Platelet-activating factor antagonists reduce excitotoxic damage in cultured neurons from embryonic chick telencephalon and protect the rat hippocampus and neocortex from ischemic injury in vivo. J Neurosci Res. 1993; 34(2):179-88. DOI: 10.1002/jnr.490340205. View

16.

Birks J, Grimley E, van Dongen M . Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003; (4):CD003120. DOI: 10.1002/14651858.CD003120. View

17.

Misonou H, Morishima-Kawashima M, Ihara Y . Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry. 2000; 39(23):6951-9. DOI: 10.1021/bi000169p. View

18.

Tariot P, Farlow M, Grossberg G, Graham S, McDonald S, Gergel I . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-24. DOI: 10.1001/jama.291.3.317. View

19.

Garcia-Merino J, Blasco-Quitez M, Ortiz-Benitez P, Puerta C . [Combined therapy in multiple sclerosis]. Rev Neurol. 2003; 36(6):545-9. View

20.

Stahl S . Antipsychotic polypharmacy: evidence based or eminence based?. Acta Psychiatr Scand. 2002; 106(5):321-2. DOI: 10.1034/j.1600-0447.2002.2e011.x. View